Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | PGD | P52209 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26007106 | 0.89 | GPR84 (0.34) | SLC22A6ALOX15FFAR3LMNAGPR84 | |
| SCHEMBL30616013 | 0.85 | ALOX15 (0.43) | SLC22A6ALOX15SMN1; SMN2LMNATHRB | |
| SCHEMBL16411803 | 0.81 | LDHA (0.33) | FFAR3THRBFFAR1 | |
| SCHEMBL9747219 | 0.80 | TSHR (0.37) | ALOX15THRBALDH1A1FFAR1 | |
| SCHEMBL2874716 | 0.79 | ALDH1A1 (0.43) | ALOX15TDP1LMNATHRBALDH1A1 | |
| SCHEMBL1878811 | 0.79 | ALDH1A1 (0.43) | ALOX15TDP1LMNATHRBALDH1A1 | |
| SCHEMBL3989533 | 0.78 | FOLH1 (0.44) | TDP1SMN1; SMN2THRB | |
| SCHEMBL21081924 | 0.77 | ALDH1A1 (0.40) | FFAR3TDP1LMNATHRBALDH1A1 | |
| SCHEMBL22906066 | 0.77 | — | — | |
| SCHEMBL4483900 | 0.77 | TDP1 (0.43) | FFAR3TDP1LMNATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436809-B | Method for preparing diethyl maleate by carrying out depolymerization on lignin under catalysis of iron oxide loaded by USY molecular sieve | 华南理工大学 | 2023-01-06 | — | — | CN | claimed |
| CN-108997340-A | Synthetic method of 5-bromo-7-azaindole | 山东轩德医药科技有限公司 | 2018-12-14 | — | — | CN | claimed |
| EP-2482996-B1 | METHOD FOR THE SPOT REPAIR OF SCRATCH-RESISTANT PAINT FILMS | BASF COATINGS GMBH (DE) | 2016-03-30 | — | — | EP | claimed |
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | claimed |
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | claimed |
| EP-1140933-B1 | PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES | AVENTIS PHARMA INC (US) | 2004-09-08 | — | — | EP | claimed |
| EP-0662970-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-6-CHLOROPURINE | SMITHKLINE BEECHAM PLC (GB) | 1995-07-19 | — | — | EP | claimed |
| EP-0319228-B1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1994-11-02 | — | — | EP | claimed |
| WO-1994007892-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-6-CHLOROPURINE | SMITHKLINE BEECHAM PLC (GB) | 1994-04-14 | — | — | WO | claimed |
| US-12600705-B2 | Heat shock protein modulators and anti-Huntington disease therapeutic agents | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| WO-2025124429-A1 | AROMATIC AMINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京康辰药业股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| US-20240327388-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240287063-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-115703792-B | Tricycle derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-4269980-A | TRANQUILIZERS; ANTICONVULSANTS | AMERICAN CYANAMID COMPANY (US) | 1981-05-26 | — | — | US | disclosed |
| US-4110116-A | Fogged direct positive silver halide emulsion containing a cyanine dye having at least one benzoxazole or benzothiazole nucleus substituted with halogen atoms | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
| US-4093812-A | MICROBIOCIDES, DISINFECTANTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4034093-A | INHIBITION OF XANTHINEOXIDASE | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-07-05 | — | — | US | disclosed |
| US-4003750-A | METHINE DYES | EASTMAN KODAK COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
| US-3865824-A | 2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines | ICN PHARMACEUTICALS | 1975-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287063-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR | MAT2A, MAT2B, MAT1A | SLC22A6 1003/4885ALOX15 3223/4885FFAR3 3782/4885 |
| US-12600705-B2 | Heat shock protein modulators and anti-Huntington disease therapeutic agents | HEATR1, HSPH1, HEATR6 | SLC22A6 2312/4885ALOX15 2750/4885FFAR3 2637/4885 |
| US-20240327388-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | QARS1, THEM6, CYP4F11 | SLC22A6 407/4885ALOX15 1335/4885FFAR3 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.